Franklin Resources
CERE

Franklin Resources’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Franklin Resources’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,613
Closed -$209K – 2407
2022
Q4 		$209K Buy
+6,613
New +$187K ﹤0.01% 1992

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Franklin Resources's CERE Position: Q1 2023 in Review

Franklin Resources sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 6,613 shares — an estimated $209K sold.

Franklin Resources first reported a position in CERE in Q4 2022 and held it in 1 quarter. The position peaked at $209K in Q4 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

  • Franklin Resources reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Franklin Resources sold 6,613 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $209K.
  • Franklin Resources first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Franklin Resources's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $209K in Q4 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on Franklin Resources's 13F filing for Q1 2023, filed 12 May 2023.